APPILI THERAPEUTICS

In The Global Race 
Against Infectious Diseases

Internal Innovation; Active In-Licensing.

Appili Therapeutics is proud to be at the forefront of global efforts to address serious infectious disease threats.

Our systematic approach to building a diverse pipeline provides investment opportunities that serve the needs of patients, payers, and clinicians. Our strategy centers on identifying unmet medical needs, rather than adhering to a specific platform or technology, and matching those needs with potential solutions in the marketplace. This approach provides financial stability and the opportunity to leverage a broad range of government and industry programs, as well as to develop transformative programs that can impact the fundamental treatment landscape for many types of infections.

Latest News

INVESTOR QUICK LINKS

VIDEO: Appili Therapeutics is well funded and working to combat infectious diseases

May 17, 2021
Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients
April 19, 2021
Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021
March 17, 2021
Appili Therapeutics to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference on Friday, March 19th
March 5, 2021
Drs. Scott Gottlieb, Syra Madad, and Josh Schimmer Examined Scientific Milestones and Public Health Challenges That Have Defined the Global Response to COVID-19, and Important Role Appili Still Has to Play During Appili Therapeutics’ Inaugural Fireside Chat